ONE-PEAK
6.12.2022 11:15:36 CET | Business Wire | Press release
One Peak, a leading investor for growth stage B2B software companies in Europe and Israel, is excited to announce the closing of One Peak Growth III at its hard cap of $1 billion. The fund was significantly oversubscribed, demonstrating strong LP demand. Building on the success of One Peak’s first two funds, the closing of One Peak Growth III brings the firm’s total assets under management to c. $2 billion. The size of the new fund makes One Peak, founded by David Klein and Humbert de Liedekerke Beaufort, the largest fund in Europe dedicated to backing fast growing B2B software companies in the $15m-$100m investment range.
Accelerating Growth
Humbert de Liedekerke Beaufort, Co-founder and Managing Partner, said: “Growth equity is a significantly underrepresented asset class in Europe versus the US and China. There are many world class founders in Europe who need capital and support to win at global scale, and One Peak fills that gap for the best B2B software companies. With Fund III, we’ll continue to partner with the most ambitious founders and support them with our sector expertise, global network, and value creation platform to build enduring companies against the backdrop of today’s macroeconomic headwinds. $15-100m is our investment sweet spot, where we act as a catalyst to accelerate growth and help companies realize their full potential.”
Deep B2B Sector Expertise
Over the past 8 years, One Peak has built a concentrated portfolio of minority stakes in category leading software companies such as Cymulate, Deepki, DocPlanner, PandaDoc, Neo4j, and Spryker Systems. The One Peak team is an active partner to the founders it backs and supports them in building lasting, category-defining companies for the long term. This includes access to some of the best B2B software operators in the world through One Peak’s Value Creation Team which is comprised of experts in sales, marketing, partnerships, product, tech, and talent.
David Klein, Co-founder and Managing Partner, said: “We are ultimately in the business of investing in exceptional founders, and we work alongside them with the same passion and dedication as they do. Our value-add is significantly enhanced by our fully integrated Value Creation Team, particularly when it comes to hiring the best talent, accelerating top line growth, driving global expansion, and improving product and technology capabilities. This is a key differentiator for our portfolio companies in building generational companies. Last but not least, we are grateful to our founders and LPs from around the globe for their continued trust.”
One Peak’s relationship-driven approach is augmented by PULSE, One Peak’s proprietary sourcing and business intelligence software platform. PULSE integrates with a plethora of data sources and continuously surfaces the most promising opportunities for new investments and bolt-on acquisitions for One Peak’s portfolio companies.
Strong Blue Chip Investor Base
Commitments to One Peak Growth III came from a diverse group of investors from the US and Europe, including blue chip university endowments, foundations, public pensions plans, insurance companies, asset managers, fund of funds, and family offices.
Proskauer Rose LLP and Van Campen Liem served as fund counsel to One Peak Growth III.
— Ends —
About One Peak
One Peak is a leading growth equity investment firm with approx. $2 billion in assets under management that invests in technology companies in the scale-up phase. One Peak provides growth capital, operating expertise and access to its extensive network to exceptional entrepreneurs, with a view to help transform innovative and rapidly growing businesses into lasting, category-defining leaders. One Peak’s investments include Ardoq, Brightflag, Coople, Cymulate, DataGuard, Deepki, DocPlanner, Emnify, HighQ, Infermedica, Keepit, Lucca, Neo4j, Orgvue, PandaDoc, Paysend, Quentic, Spryker Systems, and many more. To learn more, visit www.onepeak.tech.
Founder testimonials
“From the early days of our relationship, One Peak worked collaboratively with us to identify growth initiatives with the biggest impact. They helped us with revenue optimization, international expansion, M&A and the recruitment of world class talent. Above all, we really value the open and direct communication and are grateful for their trust, hard work, dedication, and passion to help us realize our vision.”
Mariusz Gralewski, Founder & CEO, DocPlanner
“One Peak has been a true value-add partner to us since day 1. They really are one of those rare investors that can zoom in and zoom out, talk big picture strategy and nitty-gritty operational details, and add value on the go-to-market side as well as challenge our thinking on product. Plus they are driven, passionate, have great clarity of thought, and are simply nice people – we genuinely enjoy the great cultural fit with the One Peak team.”
Emil Eifrem, Founder and CEO, Neo4j
To view this piece of content from cts.businesswire.com, please give your consent at the top of this page.
View source version on businesswire.com: https://www.businesswire.com/news/home/20221205005103/en/
About Business Wire
Subscribe to releases from Business Wire
Subscribe to all the latest releases from Business Wire by registering your e-mail address below. You can unsubscribe at any time.
Latest releases from Business Wire
Biocodex Invests €15 Million in a New Industrial Platform for Live Biotherapeutic Products5.11.2026 16:04:00 CET | Press release
Biocodex, an independent French pharmaceutical company, announces a €15 million investment to develop an industrial platform in Beauvais, France, dedicated to Live Biotherapeutic Products (LBPs) derived from the microbiome. Building on more than 70 years of expertise in living microorganisms, microbiota, fermentation and pharmaceutical manufacturing, Biocodex aims to support its partners and, ultimately, its own programs, from research through to clinical and commercial production. The project aims to strengthen healthcare and industrial sovereignty in the field of next-generation microbiome-based therapies. Scientific advances in microbiome science are opening up new therapeutic perspectives, notably in oncology, inflammatory bowel diseases, certain rare diseases and women’s health. Moving from research to pharmaceutical production requires facilities adapted to living microorganisms and pharmaceutical requirements. Open to biotechnology companies worldwide, it will support LBP progra
Experian's New Documentary RECLAIM Shows How Financial Access and Innovation Are Creating Opportunity Around the World5.11.2026 16:00:00 CET | Press release
Short film follows consumers across three countries whose stories demonstrate the power of financial inclusion, innovation and resilienceKey highlights: New Experian documentary features five individuals from the United States, Brazil and the United Kingdom whose experiences illustrate the impact of financial access and opportunity. Documentary highlights examples spanning debt relief, financial education, credit empowerment and healthcare innovation. Stories showcase how Experian's products, services and social innovation can help consumers navigate challenges and pursue personal and financial goals. For years, Almir dreamed of meeting his granddaughter in the United States. But unresolved debt stood in the way. Thousands of miles away in Arizona, Elizabeth faced mounting medical expenses after a health crisis. In London, Rochelle worked to regain control of her finances while caring for family members. Their stories, and others like them, are at the heart of RECLAIM: Stories of Passi
Saudi Fund for Development Signs Six Development Loan Agreements Worth Over USD 403 Million with Syria5.11.2026 15:32:00 CET | Press release
The Saudi Fund for Development (SFD) has signed six concessional development loan agreements worth more than USD 403 million with the Syrian Arab Republic, marking a significant step in supporting the country’s recovery through the rehabilitation of essential infrastructure, restoration of vital public services and improvement of living conditions for communities affected by years of conflict. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20261105350224/en/ HRH the Crown Prince and President of the Syrian Arab Republic Al-Sharaa witness signing of agreements (Photo: AETOSWire The agreements, signed under the directives of the Custodian of the Two Holy Mosques, King Salman bin Abdulaziz Al Saud, and His Royal Highness Prince Mohammed bin Salman bin Abdulaziz Al Saud, Crown Prince and Prime Minister, reflect the Kingdom’s continued commitment to supporting Syria’s development priorities. The signing ceremony was witnessed by Hi
Hyperice Unveils Normatec Elite Heat Legs: Integrated Heat Meets Dynamic Air Compression in a New Fully Wireless Design5.11.2026 15:00:00 CET | Press release
FSA/HSA-Eligible Recovery Boots Deliver Five Levels of Heat and Seven Levels of Compression, Available for Pre-Order Now Hyperice, a high-performance wellness brand, today announced the launch of Normatec Elite Heat Legs, the newest innovation in the award-winning Normatec line and the first Normatec product to incorporate heat directly into its line of dynamic air compression therapy. As the 2024 launch of Normatec Elite signified a transformative leap forward in recovery technology, Elite Heat demonstrates Hyperice’s relentless commitment to offering athletes and wellness enthusiasts alike the most comprehensive and intuitive recovery experiences in the world. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20261105782891/en/ Normatec Elite Heat demonstrates Hyperice’s relentless commitment to offering athletes and wellness enthusiasts alike the most comprehensive and intuitive recovery experiences in the world. “Innovation h
LPs Expect Private Markets Managers to Level Up in 2027: SS&C Intralinks Survey5.11.2026 15:00:00 CET | Press release
SS&C Technologies Holdings, Inc. (Nasdaq: SSNC) today announced the publication of the 2027 LP Survey. In association with Reuters Insights, SS&C Intralinks surveyed 400 professionals working in private markets, including 370 limited partners and allocators, to understand how the alternative investments market will change in the next 12 months.* “Alternatives once again delivered in 2026, and LPs are still committing capital, but their expectations of managers continue to rise,” said Ken Bisconti, general manager of SS&C Intralinks. “Technology and data capabilities now rank among the most important criteria for selecting managers, alongside investment strategy. Performance alone is no longer enough. For nearly one-third of allocators, a credible artificial intelligence (AI) strategy is now a prerequisite for allocating capital to a manager.” Key findings from the report include: Alternatives portfolios continue to outperform. 62% of respondents said their portfolios exceeded expectati
In our pressroom you can read all our latest releases, find our press contacts, images, documents and other relevant information about us.
Visit our pressroom
